Company Focus
Gilead Sciences
Latest Gilead Sciences News
Pharmaceutical
Following the US Food and Drug Administration's (FDA) approval of Bixlenvo (bictegravir 75mg/lenacapavir 50mg)—the smallest once-daily single tablet regimen (STR) for virologically suppressed adults with HIV—The Pharma Letter followed up with Betty Chiang, vice president of US medical affairs, virology at Gilead Sciences, to discuss the approval's significance and how the drug fits into the company's broader HIV strategy. 4 September 2026
Related News
Insights
Company Spotlight
A South Korean biotechnology company developing next-generation biobetters and biosimilars through proprietary platform technologies, with its human hyaluronidase ALT-B4 attracting a growing roster of global pharmaceutical partners.
Latest News & Features of interest to Gilead Sciences
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Bixlenvo (bictegravir 75mg/lenacapavir 50mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. 28 August 2026
Biotechnology
US biotech major Moderna plans to raise $2 billion through a private placement of convertible senior notes due 2032, offered to qualified institutional buyers under Rule 144A. Initial purchasers will get a 13-day option to take up to $300 million of additional notes, which would lift the total to $2.3 billion. 28 August 2026
Biotechnology
Eascra Biotech, a nanomedicine start-up with a laboratory in Worcester, Massachusetts, USA, has appointed Dr Andrew Goodearl, as chief scientific officer (CSO). 27 August 2026
Biotechnology
US pharma major AbbVie said it has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. 27 August 2026
Biotechnology
Summit Therapeutics (Nasdaq: SMMT) and its Chinese partner Akeso (HKG: 9926) have reported the first Phase III success for bispecific antibody ivonescimab outside lung cancer, after the drug extended survival in previously untreated advanced biliary tract cancer. 27 August 2026
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer - delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 27 August 2026
Biotechnology
Chinese innovative drug developer Haisco Pharmaceutical Group has entered an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners 26 August 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Tivicay PD tablets for oral suspension (dolutegravir) to treat HIV infection in babies from birth up to four weeks weighing at least 2 kg, in combination with other antiretroviral agents. 26 August 2026
Biotechnology
German cancer specialist Immatics today announced that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant. 25 August 2026
Biotechnology
Sales of US pharma companies Merck & Co and Moderna’s personalized cancer vaccine intismeran autogene are projected to surpass $1 billion by 2031, following positive Phase III INTerpath-001 results in high-risk resected melanoma. 25 August 2026
Latest In Brief for Gilead Sciences
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze